1-19 of 19
Frank M. Balis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

Free
Jennifer H. Foster, Stephan D. Voss, David C. Hall, Charles G. Minard, Frank M. Balis, Keith Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yael P. Mossé
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (13): 3543–3548.
https://doi.org/10.1158/1078-0432.CCR-20-4224
Published: 01 July 2021
View article titled, Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Open the PDF for Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) in another window
Includes: Supplementary data
Journal Articles

Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib

Free
Ira L. Kraft, Srivandana Akshintala, Yuelin Zhu, Haiyan Lei, Claudia Derse-Anthony, Eva Dombi, Seth M. Steinberg, Maya Lodish, Steven G. Waguespack, Oxana Kapustina, Elizabeth Fox, Frank M. Balis, Maria J. Merino, Paul S. Meltzer, John W. Glod, Jack F. Shern, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 753–765.
https://doi.org/10.1158/1078-0432.CCR-17-2101
Published: 14 February 2018
View article titled, Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Open the PDF for Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib in another window
Includes: Supplementary data
Journal Articles

Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma

Free
Elizabeth Fox, Brigitte C. Widemann, Meredith K. Chuk, Leigh Marcus, Alberta Aikin, Patricia O. Whitcomb, Maria J. Merino, Maya Lodish, Eva Dombi, Seth M. Steinberg, Samuel A. Wells, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4239–4248.
https://doi.org/10.1158/1078-0432.CCR-13-0071
Published: 31 July 2013
View article titled, Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Open the PDF for Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

Free
Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6011–6022.
https://doi.org/10.1158/1078-0432.CCR-11-3284
Published: 06 November 2012
View article titled, A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report in another window
Includes: Supplementary data
Journal Articles

Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials

Free
AeRang Kim, Eva Dombi, Jeffrey Solomon, Elizabeth Fox, Frank M. Balis, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (18): 5982–5990.
https://doi.org/10.1158/1078-0432.CCR-10-2259
Published: 14 September 2011
View article titled, Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials
Open the PDF for Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials in another window
Journal Articles

A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

Free
Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard L. Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, Susan E. Bates
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (3): 569–580.
https://doi.org/10.1158/1078-0432.CCR-10-1725
Published: 01 February 2011
View article titled, A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer
Open the PDF for A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group

Free
Shana Jacobs, Elizabeth Fox, Mark Krailo, Gwen Hartley, Fariba Navid, Leonard Wexler, Susan M. Blaney, Anne Goodwin, Wendy Goodspeed, Frank M. Balis, Peter C. Adamson, Brigitte C. Widemann
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 750–754.
https://doi.org/10.1158/1078-0432.CCR-09-1906
Published: 14 January 2010
View article titled, Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group
Open the PDF for Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children's Oncology Group in another window
Journal Articles

Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas

Free
Elizabeth Fox, Brigitte C. Widemann, Douglas S. Hawkins, Nalini Jayaprakash, Ramzi Dagher, Alberta A. Aikin, Donna Bernstein, Lauren Long, Crystal Mackall, Lee Helman, Seth M. Steinberg, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7361–7367.
https://doi.org/10.1158/1078-0432.CCR-09-0761
Published: 30 November 2009
View article titled, Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
Open the PDF for Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas in another window
Journal Articles

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

Free
Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Wendy Goodspeed, Anne Goodwin, Marie Kromplewski, Molly E. Fouts, Diane Medina, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1111–1115.
https://doi.org/10.1158/1078-0432.CCR-07-4097
Published: 15 February 2008
View article titled, A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Free
Elizabeth Fox, John M. Maris, Brigitte C. Widemann, Kysa Meek, Anne Goodwin, Wendy Goodspeed, Marie Kromplewski, Molly E. Fouts, Diane Medina, Steve Y. Cho, Susan L. Cohn, Andrew Krivoshik, Anne E. Hagey, Peter C. Adamson, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (16): 4882–4887.
https://doi.org/10.1158/1078-0432.CCR-06-0534
Published: 16 August 2006
View article titled, A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors
Open the PDF for A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors in another window
Journal Articles

Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates

Free
Shana S. Jacobs, Elizabeth Fox, Christopher Dennie, Lindsey B. Morgan, Cynthia L. McCully, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (4): 1669–1674.
https://doi.org/10.1158/1078-0432.CCR-04-1807
Published: 02 March 2005
View article titled, Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates
Open the PDF for Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates in another window
Journal Articles

A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer

Free
Peter F. Lebowitz, Jennifer Eng-Wong, Brigitte C. Widemann, Frank M. Balis, Nalini Jayaprakash, Catherine Chow, Geoff Clark, Susan B. Gantz, David Venzon, JoAnne Zujewski
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (3): 1247–1252.
https://doi.org/10.1158/1078-0432.1247.11.3
Published: 11 February 2005
View article titled, A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer
Open the PDF for A Phase I Trial and Pharmacokinetic Study of Tipifarnib, a Farnesyltransferase Inhibitor, and Tamoxifen in Metastatic Breast Cancer in another window
Journal Articles

Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates

Free
Kathleen Neville, Robert A. Parise, Patrick Thompson, Alexander Aleksic, Merrill J. Egorin, Frank M. Balis, Leticia McGuffey, Cynthia McCully, Stacey L. Berg, Susan M. Blaney
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (7): 2525–2529.
https://doi.org/10.1158/1078-0432.CCR-03-0155
Published: 08 April 2004
View article titled, Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates
Open the PDF for Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates in another window
Journal Articles

Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576

Free
Manish Agrawal, Jame Abraham, Frank M. Balis, Maureen Edgerly, Wilfred D. Stein, Susan Bates, Tito Fojo, Clara C. Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (2): 650–656.
Published: 01 February 2003
View article titled, Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576
Open the PDF for Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576 in another window
Journal Articles

Pharmacokinetics of Intrathecal Gemcitabine in Nonhuman Primates

Free
Merrill J. Egorin, Eleanor G. Zuhowski, Cynthia M. McCully, Susan M. Blaney, Jody Z. Kerr, Stacey L. Berg, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2437–2442.
Published: 01 July 2002
View article titled, Pharmacokinetics of Intrathecal Gemcitabine in Nonhuman Primates
Open the PDF for Pharmacokinetics of Intrathecal Gemcitabine in Nonhuman Primates in another window
Journal Articles

A Phase I Trial and Pharmacokinetic Study of 9- cis -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study

Free
Peter C. Adamson, Brigitte C. Widemann, Gregory H. Reaman, Nita L. Seibel, Robert F. Murphy, Andrea F. Gillespie, Frank M. Balis
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3034–3039.
Published: 01 October 2001
View article titled, A Phase I Trial and Pharmacokinetic Study of 9- cis -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study
Open the PDF for A Phase I Trial and Pharmacokinetic Study of 9- cis -Retinoic Acid (ALRT1057) in Pediatric Patients with Refractory Cancer: A Joint Pediatric Oncology Branch, National Cancer Institute, and Children’s Cancer Group Study in another window
Journal Articles

Plasma and Cerebrospinal Fluid Pharmacokinetics of O6-Benzylguanine and Analogues in Nonhuman Primates

Free
Lina Long, Stacey L. Berg, Sandip K. Roy, Cindy L. McCully, Hee-Won Song-Yoo, Robert C. Moschel, Frank M. Balis, M. Eileen Dolan
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3662–3669.
Published: 01 September 2000
View article titled, Plasma and Cerebrospinal Fluid Pharmacokinetics of O6-Benzylguanine and Analogues in Nonhuman Primates
Open the PDF for Plasma and Cerebrospinal Fluid Pharmacokinetics of O6-Benzylguanine and Analogues in Nonhuman Primates in another window
Journal Articles

Modulation of Clinical Drug Resistance in a B Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm

Free
Wyndham H. Wilson, Lynn Sorbara, William D. Figg, Erik K. Mont, Edward Sausville, Katherine E. Warren, Frank M. Balis, Ken Bauer, Mark Raffeld, Adrian M. Senderowicz, Anne Monks
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (2): 415–421.
Published: 01 February 2000
View article titled, Modulation of Clinical Drug Resistance in a B Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm
Open the PDF for Modulation of Clinical Drug Resistance in a B Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm in another window
Journal Articles

Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children‘s Cancer Group Trial

Free
Nita L. Seibel, Susan M. Blaney, Michelle O‘Brien, Mark Krailo, Ray Hutchinson, Revonda B. Mosher, Frank M. Balis, Gregory H. Reaman
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (4): 733–737.
Published: 01 April 1999
View article titled, Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children‘s Cancer Group Trial
Open the PDF for Phase I Trial of Docetaxel with Filgrastim Support in Pediatric Patients with Refractory Solid Tumors: A Collaborative Pediatric Oncology Branch, National Cancer Institute and Children‘s Cancer Group Trial in another window